SiliconBeat

Depomed got a new major shareholder earlier this month when Kings Road Investments converted 18,158 shares of the company’s preferred stock it owned into 2.9 million shares of the Menlo Park developer of drug-delivery technology. The stake made the London-based investor Depomed’s third largest shareholder.

But the investors stake didn’t come cheap, despite the fact that Depomed shares have fallen more than 40 percent Read the rest of this entry »

When thinking about biotech in the Bay Area, images of Mission Bay in S.F., or Oyster Point in South City, or even that stretch of I-80 around Emeryville come to mind. But not San Jose.

Well, a press release put out by the San Jose Redevelopment Authority Tuesday — which has spent about $19 million seeding business incubator programs, including one called the San Jose BioCenter — put an end to our ignorance. Read the rest of this entry »